University of Patras
Επιπολασμός γονιδιακών μεταλλάξεων σε ασθενείς με θηλώδες καρκίνωμα του θυρεοειδούς και έκβαση της νόσου σε ελληνικό πληθυσμό
Abstract
dc:descriptionThe incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma (PTC) ranges between 38-91% (mean 45% ) and correlates with aggressive behavior. There are no data for the Greek population. Our goal is to detect the BRAF V600E mutation and the possible synergistic role with TERTC228T / C250T mutations as prognostic indicators in Greek patients with PTC. This retrospective study includes 85 patients with PTC, with total or almost total thyroidectomy, ± lymph node cleaning who received 50-100mCi of 131I. Thyroglobulin levels (basal and stimulated), anti-thyroglobulin antibodies, and findings from whole-body scans and cervical ultrasound, 1, 3, 5 and 10 years after initial treatment were recorded. Patients were categorized as: the likelihood of recurrence of the disease (low, medium and high), the response to the initial treatment (excellent / incomplete residual disease and indeterminate) and disease course according to ATA 2015 guidelines for differentiated thyroid cancer. DNA was isolated from the histological preparations and tested for the presence of the BRAF V600E mutation and in 32 patients for t TERT C228T / C250T mutation. The initial classification of the risk of disease recurrence was performed without taking into account the presence or absence of mutations of the genes under invesigation.The BRAF V600E mutation was detected in 40 out of 82 patients (48.78%), the TERT gene mutation in 4 out of 32 patients (12.5%), which also carried the BRAF V600E.Reccurence was observed in 5 patients all of them were genotyped as BRAF positive (100%) whereas only one BRAF V600E (1/4 patients, 25%) had remote metastases.Four patients were positive for BRAF V600E and TERT C228T mutations. Two were of high risk for relapse, one of which was lost to follow-up, 2 remained with residual local disease up to 5 years of follow-up. The third was at risk and had a local relapse at 3 years of follow-up, while the 4th was low-risk with an excellent response to treatment without relapse.In conclusion, BRAF V600E mutation is detected in the Greek population in a frequency in accordance with the international literature, and its presence may be a poor prognostic factor, however administration of 131 I in all patients as well as the relatively small sample size do not allow for safe conclusions to be drawn. The aggravating role of BRAF V600E / TERT coexistence is a probability.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Agalianou, Niki
- Αγαλιανού, Νίκη
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45825